Clinical Trials Browser

Phase 1/2 × Carcinoma, Non-Small-Cell Lung × Immune Checkpoint Inhibitors × Clear all

NCT05013450 2025-12-17

Dupilumab_Metastatic NSCLC

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03504488 2025-01-15

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Phase 1/2 Completed

BreastDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Triple Negative Breast Neoplasms

NCT04721223 2024-09-19

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms